SHENZHEN, China, May 10 /PRNewswire-FirstCall/ - Hard to Treat
Diseases (HTDS; http://www.htdsmedical.com/) announces that the
company successfully acquired the first contract for its
Freeze-dried Varicella Vaccine.
After the HTDS acquired Approval for its Freeze-dried MEVAC-vari
in this Central American country (company's first Varicella vaccine
approval in Latin America), the
company closed the first contract in Guatemala and expects to ship and deliver its
vaccine in May.
A source close to the company stated, "We are thrilled to close
our first deal in less than two months after the final ministry
approval. We offer very competitive products for the developing
countries, and this is a great start for us on a market that offers
a vast field of opportunities. Varicella, or chickenpox, is
generally a mild viral illness. However, approximately 1 in 50
cases chickenpox associates with complications such as pneumonia
and encephalitis, both attributed a high mortality rate. These
complications can be fully eliminated by a simple vaccination. HTDS
continues to seek out new opportunities in this part of the world
as we are able to deliver affordable products to the parts of the
world where basic health care lags behind only due to funding."
The company reminds its shareholders and followers to monitor
PinkSheets.com Filing section and also our IR company web site
section "PRESS RELEASES AND FILINGS" TAB
http://www.minamargroup.net/ for non newsworthy corporate
updates.
For any matters relating to retail investor queries or to send
the company or its IR a message please click on the "INVESTOR
SUPPORT" TAB, or the direct link
http://www.minamargroup.net/helpdesk. In this regard, Mina Mar
Group works diligently to answer and address all the pressing
issues regarding its clients to the shareholders' satisfaction. MMG
is in constant contact with the companies, addressing, obtaining
and processing all inquiries. MMG is often one of the advisors or
IR companies utilized by the issuer. Depending on the location of
the issuer and management's availability, it may take up to several
days to address any pressing issues. In a normal course of business
and a pending transaction the issuer may opt to remain silent in
order not to lose advantage to a competitor. MMG is mindful that
sometimes shareholders want answers now, which for above reasons
cannot be fulfilled on a timely basis.
Don't be a victim. Report a stock basher to authorities. The
company is mindful that short sellers, the company competitors and
stock bashers stalk small cap Pink Sheets listed companies with
hidden agendas. Visit http://www.stockbasher.com/ and find out what
criminal and civil actions the US authorities are taking against
web sites like investorshub.com and other posters, and the remedies
available to you as an individual investor. MMG encourages the
readers to visit this investorshub.com blog and similar "investors"
web sites with an open mind. Discover for yourself why and how
USA based small businesses and the
backbone of the economy suffer. Stay informed and do not allow
entrepreneurs dreams, innovations, and their access to capital to
be thwarted as "scalpers" and day traders vigorously day in and day
out try to exploit and extinguish US innovation and progress for
quick profits.
Filings for this event are currently being reviewed and will be
filed with Pink Sheets and Client Support section in due course. To
be included in company's email database for press releases,
industry updates, and non-weekly activity in the company that may
or may not be news released, please subscribe or opt in mailer at
http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future
expectations, plans, prospects or performance of Hard to Treat
Diseases, Inc. that constitute forward-looking statements for
purposes of the safe harbor Provisions under the Private Securities
Litigation Reform Act of 1995. The words or phrases "can be,"
"expects," "may affect," "believed," "estimate," "project," and
similar words and phrases are intended to identify such
forward-looking statements. HTDS Corporation cautions you that any
forward-looking information provided by or on behalf of Hard to
Treat Diseases, Inc. is not a guarantee of future performance. None
of the information in this filing constitutes or is intended as an
offer to sell securities or investment advice of any kind. Hard to
Treat Diseases, Inc.'s actual results may differ materially from
those anticipated in such forward-looking statements as a result of
various important factors, some of which are beyond Hard to Treat
Diseases, Inc.'s control. In addition to those discussed in Hard to
Treat Diseases, Inc.'s press releases, public filings, and
statements by Hard to Treat Diseases, Inc.'s management, including,
but not limited to, Hard to Treat Diseases, Inc.'s estimate of the
sufficiency of its existing capital resources, Hard to Treat
Diseases, Inc.'s ability to raise additional capital to fund future
operations, HTDS Corporation's ability to repay its existing
indebtedness, the uncertainties involved in estimating market
opportunities and, in identifying contracts which match Hard to
Treat Diseases, Inc.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which
such statements were made. Hard to Treat Diseases, Inc. does not
undertake any obligation to publicly update any forward-looking
statement to reflect events or circumstances after the date on
which any such statement is made or to reflect the occurrence of
unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only,
please contact medicalinfo@htdsmedical.com; For any corporate
matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases